The article reports developments related to drugs and devices. A novel drug treatment for benign prostatic hyperplasia has recommended continuation of the multicenter trial on the basis of unblinded results to date. A 7-year study validating the role of three biomarkers as indicators of prostate cancer aggressiveness has been completed. General Electric Healthcare signed a licensing agreement with PhotoCure ASA to market an optical molecular imaging agent.
Processing Request
No Comments.